LL-37

• Immune support (unproven for injection)recommended

  Community practice, not from a label or trial: bottom of the 50-100 mcg daily range. No injected-use trial.

• Community practice, not from a label or trial: 50 to 100 mcg daily by subcutaneous injection, for 4 to 8 weeks (Dr Pat Taylor page; its own research score is 5/10, "limited clinical data").
• Trial dose (topical, not injected): 0.5 or 1.6 mg/mL applied twice weekly for 13 weeks after a 3-week placebo run-in, with compression (PubMed 34687253).

Route: Subcutaneous (community figure); topical in the trial.

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Placeholder 1 mg vial plus 2 mL gives 500 mcg/mL, so 50 mcg is 10 units. This is arithmetic, not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

4 to 8 weeks, or as directed for acute conditions (community page); rest length not stated.

Why:

• The source gives no rest period.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Not an FDA-approved drug. FDA removed it from Category 2 on April 15 2026 (nominations withdrawn), which does not make it compoundable; it was not in the July 2026 committee votes and is slated for review by February 2027. Check current status.

Common side effects:

• Topical trial: well tolerated and safe at both strengths (PubMed 34687253); this does not cover injection.
• Community page lists injection-site irritation, mild local inflammation, infrequent headache and possible mast cell activation in sensitive people.
• Same page lists pregnancy or breastfeeding, active autoimmune skin conditions such as psoriasis or rosacea, mast cell activation disorder, and immunosuppressive therapy as cautions.

Stop and call your prescriber if:

• Hives, flushing or trouble breathing
• Spreading redness, swelling or fever at an injection site
• A flare of an existing skin or autoimmune condition

No reliable source names a biomarker for this compound.

• PubMed 34687253: HEAL LL-37 phase IIb trial, topical, venous leg ulcers, 148 patients (2021)
• Dr Pat Taylor LL-37 page: community dose, cycle, cautions (secondary source)
• Frier Levitt: FDA removes 12 peptides from Category 2 (April 2026)
• McDermott: LL-37 still awaiting advisory committee review (by Feb 2027)